Diamond Scientific Co. v. Ambico, Inc. And Clarence Joseph Welter

848 F.2d 1220, 6 U.S.P.Q. 2d (BNA) 2028, 1988 U.S. App. LEXIS 7448, 57 U.S.L.W. 2012
CourtCourt of Appeals for the Federal Circuit
DecidedJune 3, 1988
DocketAppeal 88-1042
StatusPublished
Cited by89 cases

This text of 848 F.2d 1220 (Diamond Scientific Co. v. Ambico, Inc. And Clarence Joseph Welter) is published on Counsel Stack Legal Research, covering Court of Appeals for the Federal Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Diamond Scientific Co. v. Ambico, Inc. And Clarence Joseph Welter, 848 F.2d 1220, 6 U.S.P.Q. 2d (BNA) 2028, 1988 U.S. App. LEXIS 7448, 57 U.S.L.W. 2012 (Fed. Cir. 1988).

Opinions

DAVIS, Circuit Judge.

This appeal from an order of the United States District Court for the Southern District of Iowa granting plaintiff's motion to strike three affirmative defenses is before us by permission, to decide whether the doctrine of assignor estoppel prevents this assignor-inventor and his company, who are sued for infringement, from challenging the validity of the patents previously assigned by him to the assignee. We affirm.

Appellee Diamond Scientific Co. (Diamond) employed Dr. Clarence Welter from 1959 until 1974. During that time, Dr. Welter invented a vaccine against gastroenteritis in swine, and filed a patent application for “Transmissible Gastroenteritis Vaccines and Methods of Producing the Same.” While making this patent application, Dr. Welter assigned all of the rights in the patents to Diamond Laboratories, Inc. (the predecessor of Diamond). Eventually, Diamond’s predecessor was awarded the following patents from this application: No. 3,479,430; No. 3,585,108; and No. 3,704,203.

In 1974 Dr. Welter left Diamond, where he had become a vice-president, and formed his own company, appellant Ambico, Inc. (Ambico). Ambico began manufacturing and selling a gastroenteritis vaccine for swine. Diamond began this patent infringement suit against Ambico-and Dr. Welter, claiming infringement of the three patents that Dr. Welter had assigned to Diamond. The defendants’ answer raised, among other defenses, three grounds for patent invalidity: 35 U.S.C. § 112 (inadequate disclosure); 35 U.S.C. § 102 (lack of novelty); and 35 U.S.C. § 103 (obviousness). Diamond’s motion to strike these three defenses asserted the doctrine of assignor estoppel. The district court granted Diamond’s motion, 666 F.Supp. 163 (S.D. Iowa 1987), and this appeal followed.

The central issue to be decided is whether in this case the assignor-inventor of the patents (or a company in privity with him) can defend the infringement suit brought by the assignee by challenging the validity of the patents previously assigned, or whether the equitable doctrine of assignor estoppel prevents the assignor from claiming that the patents are invalid.

I.

This is the first opportunity presented to this court to examine the doctrine of assignor estoppel. Although the Supreme Court has examined this doctrine or a related doctrine — licensee estoppel — several times this century, its opinions have hardly been definite or definitive.

Beginning with Westinghouse Elec. & Mfg. Co. v. Formica Insulation Co., 266 U.S. 342, 45 S.Ct. 117, 69 L.Ed. 316 (1924), the Supreme Court endorsed the rule that an assignor can be estopped from challenging the validity of the assigned patent when the assignor is sued by the assignee for infringement of the assigned patent. This estoppel bars only the assignor (and those in privity with the assignor), leaving everyone else free to try to invalidate the patent. The Court did, however, limit the estoppel by allowing the assignor to present evidence of the state of the art for the sole purpose of construing and narrowing the claims of the patent. Id. at 350, 45 S.Ct. at 120. This accommodation permitted the assignor to defend against the infringement suit by attempting to show that the accused device fell outside the proper scope of the claims of the patent in suit, yet prevented the assignor from attacking the patent’s validity.

In Scott Paper Co. v. Marcalus Mfg. Co., 326 U.S. 249, 66 S.Ct. 101, 90 L.Ed. 47 (1945), the Court sidestepped a reexami[1223]*1223nation of the merits of the assignor estop-pel doctrine by once more carving an exception from the general rule. In that case, the defendant-assignor contended that the patent claimed to be infringed represented the same invention as a previously expired patent found in the prior art. The Court held that the doctrine of assignor estoppel was not available to the assignee “to foreclose the assignor of a patent from asserting the right to make use of the prior art invention of an expired patent, which anticipates that of the assigned patent....” Id. at 257, 66 S.Ct. at 105. The Court found that the application of the doctrine in that instance was incompatible “with the patent laws which dedicate to public use the invention of an expired patent.” Id. at 258, 66 S.Ct. at 105. Scott Paper was a less-than-enthusiastic acknowledgement of assignor estoppel, but the Court was careful to distinguish its decision from previous applications of the doctrine: “To whatever extent that doctrine may be deemed to have survived the Formica decision or to be restricted by it, we think that case is not controlling here.” Id. at 254, 66 S.Ct. at 103.

Scott Paper is the most recent word from the Supreme Court on assignor estop-pel. However, in Lear, Inc. v. Adkins, 395 U.S. 653, 89 S.Ct. 1902, 23 L.Ed.2d 610 (1969), the Court addressed the somewhat analogous doctrine of licensee estoppel. Reasoning that “the equities of the licensor do not weigh very heavily when they are balanced against the important public interest in permitting full and free competition in the use of ideas which are in reality a part of the public domain[,]” the Court explicitly abolished licensee estoppel. Although Lear involved the licensing, rather than the assignment, of a patent, the opinion reviewed the history of “patent estop-pel” in general, and indicated that the Court’s previous decisions had sapped much of the vitality, if not the logic, from the assignment estoppel doctrine as well. Recalling Scott Paper, the Court asked, “If patent policy forbids estoppel when the old owner attempts to show that he did no more than copy an expired patent, why should not the old owner also be permitted to show that the invention lacked novelty because it could be found in a technical journal or because it was obvious to one knowledgeable in the art? ... The Scott exception had undermined the very basis of the ‘general rule.’ ” Lear, 395 U.S. at 666, 89 S.Ct. at 1909.

Lear resolved the issue of licensee estop-pel by writing its obituary; but for courts wrestling with assignor estoppel it was less clear whether Lear had also sounded the death knell for that doctrine. Certainly, there was nothing in its holding that eliminated the doctrine. Beyond the questioning dicta in Lear, the Court has left assignment estoppel untouched for the past nineteen years.

II.

The federal court cases, decided either shortly before Lear or since then, that discuss the doctrine of assignor estoppel reveal some uncertainty about the continued vitality of the doctrine. At least two courts have acknowledged the doctrine, although rejecting on the facts its application to the cases before them. Nationwide Chemical Corp. v. Wright, 458 F.Supp. 828, 840, 192 USPQ 95, 105 (M.D.Fla.1976), aff'd 584 F.2d 714

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Minerva Surgical, Inc. v. Hologic, Inc.
594 U.S. 559 (Supreme Court, 2021)
Hologic, Inc. v. Minerva Surgical, Inc.
957 F.3d 1256 (Federal Circuit, 2020)
Arista Networks, Inc. v. Cisco Systems, Inc.
908 F.3d 792 (Federal Circuit, 2018)
Verinata Health, Inc. v. Ariosa Diagnostics, Inc.
329 F. Supp. 3d 1070 (N.D. California, 2018)
Hologic, Inc. v. Minerva Surgical, Inc.
325 F. Supp. 3d 507 (D. Delaware, 2018)
Gemshares LLC v. Lipton
N.D. Illinois, 2018
Milwaukee Electric Tool Corp. v. Snap-On Inc.
271 F. Supp. 3d 990 (E.D. Wisconsin, 2017)
Ocean Tomo, LLC v. PatentRatings, LLC
262 F. Supp. 3d 553 (N.D. Illinois, 2017)
Mentor Graphics Corporation v. Eve-Usa, Inc.
851 F.3d 1275 (Federal Circuit, 2017)
Igt v. Aristocrat Technologies, Inc.
646 F. App'x 1015 (Federal Circuit, 2016)
MAG Aerospace Industries, Inc. v. B/E Aerospace, Inc.
816 F.3d 1374 (Federal Circuit, 2016)
Esoterix Genetic Laboratories LLC v. Qiagen Inc.
133 F. Supp. 3d 349 (D. Massachusetts, 2015)
Ocean Tomo, LLC v. Barney
133 F. Supp. 3d 1107 (N.D. Illinois, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
848 F.2d 1220, 6 U.S.P.Q. 2d (BNA) 2028, 1988 U.S. App. LEXIS 7448, 57 U.S.L.W. 2012, Counsel Stack Legal Research, https://law.counselstack.com/opinion/diamond-scientific-co-v-ambico-inc-and-clarence-joseph-welter-cafc-1988.